The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Ronald N. Jones

JMI Laboratories

North Liberty

IA 52317

USA

[email]@jmilabs.com

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • JMI Laboratories, North Liberty, IA 52317, USA. 2001 - 2011
  • JMI Laboratories, 345 Beaver Kreek Centre, Ste A, North Liberty, USA. 2010
  • JMI Laboratories, North Liberty, IA 52317, USA; Tufts University School of Medicine, USA. 2008
  • University of Iowa College of Medicine, Iowa City, USA. 2001

References

  1. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. Jones, R.N., Farrell, D.J., Mendes, R.E., Sader, H.S. J. Antimicrob. Chemother. (2011) [Pubmed]
  2. In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United States. Jones, R.N., Mendes, R.E., Sader, H.S., Castanheira, M. Clin. Infect. Dis. (2011) [Pubmed]
  3. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. Jones, R.N., Mendes, R.E., Sader, H.S. J. Antimicrob. Chemother. (2010) [Pubmed]
  4. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Jones, R.N. Clin. Infect. Dis. (2010) [Pubmed]
  5. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Jones, R.N., Jacobs, M.R., Sader, H.S. Int. J. Antimicrob. Agents (2010) [Pubmed]
  6. MIC quality control guidelines and disk diffusion test optimization for CEM-101, a novel fluoroketolide. Jones, R.N., Ross, J.E., Rhomberg, P.R. J. Clin. Microbiol. (2010) [Pubmed]
  7. In vitro activity of iclaprim and comparison agents tested against Neisseria gonorrhoeae including medium growth supplement effects. Jones, R.N., Biedenbach, D.J., Sader, H.S. Diagn. Microbiol. Infect. Dis. (2009) [Pubmed]
  8. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. Jones, R.N., Ross, J.E., Bell, J.M., Utsuki, U., Fumiaki, I., Kobayashi, I., Turnidge, J.D. Diagn. Microbiol. Infect. Dis. (2009) [Pubmed]
  9. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. Jones, R.N., Kohno, S., Ono, Y., Ross, J.E., Yanagihara, K. Diagn. Microbiol. Infect. Dis. (2009) [Pubmed]
  10. In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens. Jones, R.N., Bell, J.M., Sader, H.S., Turnidge, J.D., Stilwell, M.G. Diagn. Microbiol. Infect. Dis. (2009) [Pubmed]
  11. TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens. Jones, R.N., Moet, G.J., Sader, H.S., Mendes, R.E., Castanheira, M. J. Antimicrob. Chemother. (2009) [Pubmed]
  12. Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains. Jones, R.N., Biedenbach, D.J., Ambrose, P.G., Wikler, M.A. Diagn. Microbiol. Infect. Dis. (2008) [Pubmed]
  13. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Jones, R.N., Kirby, J.T., Rhomberg, P.R. Diagn. Microbiol. Infect. Dis. (2008) [Pubmed]
  14. Antimicrobial activity of DC-159a, a new fluoroquinolone, against 1,149 recently collected clinical isolates. Jones, R.N., Fritsche, T.R., Sader, H.S. Antimicrob. Agents Chemother. (2008) [Pubmed]
  15. In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation. Jones, R.N., Fritsche, T.R., Moet, G.J. Diagn. Microbiol. Infect. Dis. (2008) [Pubmed]
  16. United States resistance surveillance results for linezolid (LEADER Program for 2007). Jones, R.N., Ross, J.E., Castanheira, M., Mendes, R.E. Diagn. Microbiol. Infect. Dis. (2008) [Pubmed]
  17. Key considerations in the treatment of complicated staphylococcal infections. Jones, R.N. Clin. Microbiol. Infect. (2008) [Pubmed]
  18. Molecular characterization of Staphylococcus aureus isolates from a 2005 clinical trial of uncomplicated skin and skin structure infections. Jones, R.N., Nilius, A.M., Akinlade, B.K., Deshpande, L.M., Notario, G.F. Antimicrob. Agents Chemother. (2007) [Pubmed]
  19. Development of anidulafungin for disk diffusion susceptibility testing against Candida spp. Jones, R.N., Kirby, J.T., Messer, S.A., Sheehan, D.J. Diagn. Microbiol. Infect. Dis. (2007) [Pubmed]
  20. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Jones, R.N., Fritsche, T.R., Sader, H.S., Ross, J.E. Diagn. Microbiol. Infect. Dis. (2007) [Pubmed]
  21. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae. Jones, R.N., Sader, H.S., Stilwell, M.G., Fritsche, T.R. Diagn. Microbiol. Infect. Dis. (2007) [Pubmed]
  22. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values. Jones, R.N., Fritsche, T.R., Sader, H.S., Stilwell, M.G. Diagn. Microbiol. Infect. Dis. (2007) [Pubmed]
  23. Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Jones, R.N., Fritsche, T.R., Sader, H.S., Ross, J.E. Diagn. Microbiol. Infect. Dis. (2007) [Pubmed]
  24. Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem. Jones, R.N., Sader, H.S., Fritsche, T.R., Janechek, M.J. Diagn. Microbiol. Infect. Dis. (2007) [Pubmed]
  25. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Jones, R.N., Sader, H.S., Fritsche, T.R., Pottumarthy, S. Diagn. Microbiol. Infect. Dis. (2007) [Pubmed]
  26. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. Jones, R.N., Ferraro, M.J., Reller, L.B., Schreckenberger, P.C., Swenson, J.M., Sader, H.S. J. Clin. Microbiol. (2007) [Pubmed]
  27. Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program. Jones, R.N., Stilwell, M.G., Hogan, P.A., Sheehan, D.J. Antimicrob. Agents Chemother. (2007) [Pubmed]
  28. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Jones, R.N. Clin. Infect. Dis. (2006) [Pubmed]
  29. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. Jones, R.N., Ross, J.E., Fritsche, T.R., Sader, H.S. J. Antimicrob. Chemother. (2006) [Pubmed]
  30. Contemporary antimicrobial activity of triple antibiotic ointment: a multiphased study of recent clinical isolates in the United States and Australia. Jones, R.N., Li, Q., Kohut, B., Biedenbach, D.J., Bell, J., Turnidge, J.D. Diagn. Microbiol. Infect. Dis. (2006) [Pubmed]
  31. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Jones, R.N., Stilwell, M.G., Sader, H.S., Fritsche, T.R., Goldstein, B.P. Diagn. Microbiol. Infect. Dis. (2006) [Pubmed]
  32. Update on the cefdinir spectrum and potency against pathogens isolated from uncomplicated skin and soft tissue infections in North America: are we evaluating the orally administered cephalosporins correctly?. Jones, R.N., Sader, H.S. Diagn. Microbiol. Infect. Dis. (2006) [Pubmed]
  33. Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program. Jones, R.N., Sader, H.S., Fritsche, T.R., Hogan, P.A., Sheehan, D.J. J. Clin. Microbiol. (2006) [Pubmed]
  34. Quality control guidelines for testing gram-negative control strains with polymyxin B and colistin (polymyxin E) by standardized methods. Jones, R.N., Anderegg, T.R., Swenson, J.M. J. Clin. Microbiol. (2005) [Pubmed]
  35. Antimicrobial activity of LBM415 (NVP PDF-713) tested against pathogenic Neisseria spp. (Neisseria gonorrhoeae and Neisseria meningitidis). Jones, R.N., Sader, H.S., Fritsche, T.R. Diagn. Microbiol. Infect. Dis. (2005) [Pubmed]
  36. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms. Jones, R.N., Sader, H.S., Fritsche, T.R. Diagn. Microbiol. Infect. Dis. (2005) [Pubmed]
  37. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae. Jones, R.N., Fritsche, T.R., Sader, H.S. Diagn. Microbiol. Infect. Dis. (2005) [Pubmed]
  38. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases. Jones, R.N., Craig, W.A., Ambrose, P.G., Dudley, M.N., Pottumarthy, S. Diagn. Microbiol. Infect. Dis. (2005) [Pubmed]
  39. Activity of faropenem tested against Neisseria gonorrhoeae isolates including fluoroquinolone-resistant strains. Jones, R.N., Critchley, I.A., Whittington, W.L., Janjic, N., Pottumarthy, S. Diagn. Microbiol. Infect. Dis. (2005) [Pubmed]
  40. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004. Jones, R.N., Mendes, C., Turner, P.J., Masterton, R. Diagn. Microbiol. Infect. Dis. (2005) [Pubmed]
  41. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. Jones, R.N., Fritsche, T.R., Sader, H.S., Goldstein, B.P. J. Chemother (2005) [Pubmed]
  42. Comparisons of the in vitro susceptibility testing results for garenoxacin using six different national methods: report from the garenoxacin international bridging study. Jones, R.N., Gordon, K.A., Biedenbach, D.J. J. Antimicrob. Chemother. (2004) [Pubmed]
  43. Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. Jones, R.N., Streit, J.M., Fritsche, T.R. Int. J. Antimicrob. Agents (2004) [Pubmed]
  44. Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates. Jones, R.N., Moet, G.J., Sader, H.S., Fritsche, T.R. J. Antimicrob. Chemother. (2004) [Pubmed]
  45. Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates. Jones, R.N., Fritsche, T.R., Sader, H.S. Diagn. Microbiol. Infect. Dis. (2004) [Pubmed]
  46. Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999-2002). Jones, R.N., Sader, H.S., Fritsche, T.R. Diagn. Microbiol. Infect. Dis. (2004) [Pubmed]
  47. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. Jones, R.N., Huynh, H.K., Biedenbach, D.J., Fritsche, T.R., Sader, H.S. J. Antimicrob. Chemother. (2004) [Pubmed]
  48. Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003). Jones, R.N., Deshpande, L., Fritsche, T.R., Sader, H.S. Diagn. Microbiol. Infect. Dis. (2004) [Pubmed]
  49. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Jones, R.N., Huynh, H.K., Biedenbach, D.J. Antimicrob. Agents Chemother. (2004) [Pubmed]
  50. Evaluation of the contemporary occurrence rates of metallo-beta-lactamases in multidrug-resistant Gram-negative bacilli in Japan: report from the SENTRY Antimicrobial Surveillance Program (1998-2002). Jones, R.N., Deshpande, L.M., Bell, J.M., Turnidge, J.D., Kohno, S., Hirakata, Y., Ono, Y., Miyazawa, Y., Kawakama, S., Inoue, M., Hirata, Y., Toleman, M.A. Diagn. Microbiol. Infect. Dis. (2004) [Pubmed]
  51. Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections. Fritsche, T.R., Jones, R.N. Int. J. Antimicrob. Agents (2004) [Pubmed]
  52. Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000). Jones, R.N., Biedenbach, D.J., Gales, A.C. Int. J. Antimicrob. Agents (2003) [Pubmed]
  53. Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001). Jones, R.N., Biedenbach, D.J. Diagn. Microbiol. Infect. Dis. (2003) [Pubmed]
  54. Results of the survey of the quality assurance for commercially prepared microbiology media. Update from the College of American Pathologists Microbiology Surveys Program (2001). Jones, R.N., Krisher, K., Bird, D.S. Arch. Pathol. Lab. Med. (2003) [Pubmed]
  55. Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000-2001): report from the SENTRY Antimicrobial Surveillance Program. Jones, R.N., Biedenbach, D.J., Beach, M.L. Diagn. Microbiol. Infect. Dis. (2003) [Pubmed]
  56. Validation of commercial dry-form broth microdilution panels for susceptibility testing of AZD2563, a new long-acting oxazolidinone. Jones, R.N., Anderegg, T.R., Biedenbach, D.J. Clin. Microbiol. Infect. (2003) [Pubmed]
  57. Quinupristin-dalfopristin resistance in Streptococcus pneumoniae: novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY antimicrobial surveillance program. Jones, R.N., Farrell, D.J., Morrissey, I. Antimicrob. Agents Chemother. (2003) [Pubmed]
  58. Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe. Jones, R.N., Pfaller, M.A. Clin. Microbiol. Infect. (2003) [Pubmed]
  59. Salmonella bloodstream infections: report from the SENTRY Antimicrobial Surveillance Program (1997-2001). Stephen, J.M., Toleman, M.A., Walsh, T.R., Jones, R.N. Int. J. Antimicrob. Agents (2003) [Pubmed]
  60. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Jones, R.N. Semin. Respir. Crit. Care. Med (2003) [Pubmed]
  61. Tiamulin activity against fastidious and nonfastidious veterinary and human bacterial isolates: initial development of in vitro susceptibility test methods. Jones, R.N., Pfaller, M.A., Rhomberg, P.R., Walter, D.H. J. Clin. Microbiol. (2002) [Pubmed]
  62. In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual gram-positive species. Jones, R.N., Biedenbach, D.J., Anderegg, T.R. Diagn. Microbiol. Infect. Dis. (2002) [Pubmed]
  63. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Jones, R.N., Della-Latta, P., Lee, L.V., Biedenbach, D.J. Diagn. Microbiol. Infect. Dis. (2002) [Pubmed]
  64. Ciprofloxacin as broad-spectrum empiric therapy--are fluoroquinolones still viable monotherapeutic agents compared with beta-lactams: data from the MYSTIC Program (US)?. Jones, R.N., Pfaller, M.A. Diagn. Microbiol. Infect. Dis. (2002) [Pubmed]
  65. AZD2563, a new oxazolidinone: bactericidal activity and synergy studies combined with gentamicin or vancomycin against staphylococci and streptococcal strains. Jones, R.N., Anderegg, T.R., Deshpande, L.M. Diagn. Microbiol. Infect. Dis. (2002) [Pubmed]
  66. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000). Jones, R.N., Kirby, J.T., Beach, M.L., Biedenbach, D.J., Pfaller, M.A. Diagn. Microbiol. Infect. Dis. (2002) [Pubmed]
  67. Fluoroquinolones for the treatment of outpatient community-acquired pneumonia. Jones, R.N., Mandell, L.A. Diagn. Microbiol. Infect. Dis. (2002) [Pubmed]
  68. Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae. Jones, R.N., Andes, D.R., Mandell, L.A., Gothelf, S., Ehrhardt, A.F., Nicholson, S.C. Diagn. Microbiol. Infect. Dis. (2002) [Pubmed]
  69. Re-evaluations of disk diffusion quality control ranges for 11 drugs: report from the QC working group of the national committee for clinical laboratory standards. Jones, R.N., Cullen, S. Int. J. Antimicrob. Agents (2002) [Pubmed]
  70. A comparison of the antimicrobial activity of meropenem and selected broad-spectrum antimicrobials tested against multi-drug resistant Gram-negative bacilli including bacteraemic Salmonella spp.: initial studies for the MYSTIC programme in India. Jones, R.N., Rhomberg, P.R., Varnam, D.J., Mathai, D. Int. J. Antimicrob. Agents (2002) [Pubmed]
  71. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. Jones, R.N., Deshpande, L.M., Mutnick, A.H., Biedenbach, D.J. J. Antimicrob. Chemother. (2002) [Pubmed]
  72. Microbiology of newer fluoroquinolones: focus on respiratory pathogens. Jones, R.N. Diagn. Microbiol. Infect. Dis. (2002) [Pubmed]
  73. Antimicrobial activity of broad-spectrum agents tested against Gram-negative bacilli resistant to ceftazidime: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Jones, R.N., Varnam, D.J. Diagn. Microbiol. Infect. Dis. (2002) [Pubmed]
  74. In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains. Jones, R.N. J. Chemother (2001) [Pubmed]
  75. Cefditoren in vitro activity and spectrum: a review of international studies using reference methods. Jones, R.N., Pfaller, M.A., Jacobs, M.R., Appelbaum, P.C., Fuchs, P.C. Diagn. Microbiol. Infect. Dis. (2001) [Pubmed]
  76. Determining the value of antimicrobial surveillance programs. Jones, R.N., Masterton, R. Diagn. Microbiol. Infect. Dis. (2001) [Pubmed]
 
WikiGenes - Universities